Medical Cannabinoids for Cancer Cachexia: A Systematic Review and Meta-Analysis
Wang et al.·BioMed Research InternationalImpact 1.0
GemischtGRADEHoch34 Zitate
Stichprobek = 3 Studien n = 592 Pat.
Dauerunklar
KontrollePlacebo
EndpunktAppetit / Lebensqualität
Verblindungunklar
DesignMeta-Analyse
”Kernaussage
Cannabinoide erhöhten den Appetit, verschlechterten aber die Lebensqualität und führten zu häufigen Nebenwirkungen.
Zusammenfassung
Systematische Review und Meta-Analyse zu medizinischen Cannabinoiden bei Tumor-Kachexie; Analyse von RCTs zu Appetit, Gewicht und Lebensqualität. Evidenz für moderate Verbesserung von Appetit und Übelkeit, aber limitierter Effekt auf Gewichtszunahme.
P
PopulationKrebspatienten mit Tumorkachexie, n=592 gepoolt aus 3 RCTs
OutcomeAppetit-Steigerung (MD 0.27, 95% CI -0.51 bis 1.04), jedoch Verschlechterung der Lebensqualität (MD -12.39, 95% CI -24.21 bis -0.57, n=2 Studien); 607 unerwünschte Ereignisse (496 Cannabinoid-Gruppe vs. 111 Placebo)
Vertrauen in die Evidenz
Sehr niedrigNiedrigModeratHoch
Hoch
Höchste von vier GRADE-Stufen, die Effektschätzung ist sehr verlässlich.
Objectives: Cancer cachexia (CCA) is an intractable and ineffective metabolic syndrome that attacks 50-80% of cancer patients. It reduces patient's life quality, affects the efficacy of treatment, and then increases their mortality; however, there are no established therapeutic strategies for CCA in the world. In this study, we assess the positive and negative effects of cannabinoid in the treatment of CCA.
Methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, MEDLINE, EMBASE, Web of Science, and PubMed up to December 2017.
Results: Of the 256 screened studies, three studies with a total of 592 participants were included. Compared with placebo, cannabinoid increased the appetite (MD 0.27, 95% CI -0.51 to 1.04; n= 3) but failed to improve the overall quality of life (QOL; MD -12.39, 95% CI [-24.21 to -0.57; n = 2), and a total of 441 patients had 607 adverse events (AEs; 496 in the cannabinoid group and 111 in the placebo group).
Conclusions: Our analysis showed cannabinoid is effective in increasing appetite in cancer patients. However, it declines the quality of life, which may be due to the side effects of cannabinoid.